Evidence map›Paper›PMID 25775018›Full record

ArticlePloS one2015

Cyclosporin a disrupts notch signaling and vascular lumen maintenance.

Raghav Pandey, Mark A Botros, Benjamin A Nacev, Allan R Albig

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Mitochondrial Permeability Transition in Stem Cells, Development, and Disease.Advances in experimental medicine and biology · 2023
    Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Raghav PandeyDepartment of Cancer and Cell Biology, University of Cincinnati, Cincinnati, Ohio, United States of America.
Mark A BotrosDepartment of Biology, Duke University, Durham, North Carolina, United States of America.
Benjamin A NacevDepartment of Pharmacology and Molecular Sciences, and Medical Scientist Training Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Allan R AlbigDepartment of Biology, Boise State University, Boise, Idaho, United States of America.

Funding

Women's health: interplay of maternal diet and key demographics on neurological health in the rural frontier and remote WestP20GM103408 · NIGMS · UNIVERSITY OF IDAHO · PI Scott A Minnich · 2012 to 2026
$59.8M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007309 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 1985 to 2019
$43.2M
UNDERGRADUATE COLLEGE OUTREACH PROGRAMP20RR016454 · NCRR · UNIVERSITY OF IDAHO · PI CHASE, JENNIFER R · 2001 to 2011
$35.3M
VPS35 D620N inhibits autophagy through disrupted hyaluronic acid-CD44 signalingP20GM109095 · NIGMS · BOISE STATE UNIVERSITY · PI OXFORD, JULIA THOM · 2014 to 2023
$22.7M
Mechanisms by which MAGP-2 Promotes AngiogenesisR15CA133829 · NCI · INDIANA STATE UNIVERSITY · PI ALBIG, ALLAN R · 2009 to 2010
$284k
NCI NIH HHS 3R15CA133829-01A1S1NCI NIH HHS R15 CA133829NCRR NIH HHS P20 RR016454NIGMS NIH HHS P20 GM103408NIGMS NIH HHS P20 GM109095NIGMS NIH HHS T32 GM007309NIGMS NIH HHS T32GM07309
6 · The paper itself

Abstract

Cyclosporin A (CSA) suppresses immune function by blocking the cyclophilin A and calcineurin/NFAT signaling pathways. In addition to immunosuppression, CSA has also been shown to have a wide range of effects in the cardiovascular system including disruption of heart valve development, smooth muscle cell proliferation, and angiogenesis inhibition. Circumstantial evidence has suggested that CSA might control Notch signaling which is also a potent regulator of cardiovascular function. Therefore, the goal of this project was to determine if CSA controls Notch and to dissect the molecular mechanism(s) by which CSA impacts cardiovascular homeostasis. We found that CSA blocked JAG1, but not Dll4 mediated Notch1 NICD cleavage in transfected 293T cells and decreased Notch signaling in zebrafish embryos. CSA suppression of Notch was linked to cyclophilin A but not calcineurin/NFAT inhibition since N-MeVal-4-CsA but not FK506 decreased Notch1 NICD cleavage. To examine the effect of CSA on vascular development and function, double transgenic Fli1-GFP/Gata1-RFP zebrafish embryos were treated with CSA and monitored for vasculogenesis, angiogenesis, and overall cardiovascular function. Vascular patterning was not obviously impacted by CSA treatment and contrary to the anti-angiogenic activity ascribed to CSA, angiogenic sprouting of ISV vessels was normal in CSA treated embryos. Most strikingly, CSA treated embryos exhibited a progressive decline in blood flow that was associated with eventual collapse of vascular luminal structures. Vascular collapse in zebrafish embryos was partially rescued by global Notch inhibition with DAPT suggesting that disruption of normal Notch signaling by CSA may be linked to vascular collapse. However, multiple signaling pathways likely cause the vascular collapse phenotype since both cyclophilin A and calcineurin/NFAT were required for normal vascular function. Collectively, these results show that CSA is a novel inhibitor of Notch signaling and vascular function in zebrafish embryos.

Indexed as

AnimalsCalcineurinCalcium-Binding ProteinsCyclophilin ACyclosporineEmbryo, NonmammalianGene Expression RegulationHEK293 CellsHumansIntercellular Signaling Peptides and ProteinsJagged-1 ProteinMembrane ProteinsNeovascularization, PhysiologicReceptors, NotchSerrate-Jagged ProteinsSignal TransductionCalcineurinCalcium-Binding ProteinsCyclophilin ACyclosporineIntercellular Signaling Peptides and Proteinsjag1a protein, zebrafishJAG1 protein, humanJagged-1 ProteinMembrane ProteinsReceptors, NotchSerrate-Jagged ProteinsZebrafish Proteins

Identifiers

PMID25775018
PMCPMC4361394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.